Developer docs
API playgroundTry for free, no card

Search company profiles

BullFrog AI

Full company profile

uuid00004rd

Namestring
BullFrog AI
Legal namestring
Bullfrog AI Holdings, Inc.
Websiteurl
bullfrogai.com
Company typeenum
Public
Founded yearint
2021
Descriptiontext

BullFrog AI Holdings, Inc. (NASDAQ: BFRG) is a publicly traded, AI-focused drug development technology company founded in 2021 and headquartered in Gaithersburg, Maryland. It sells an end-to-end explainable AI workflow to pharmaceutical, biotechnology, and research institution buyers, anchored on three integrated products: bfPREP™, which cleans and harmonizes fragmented clinical, multi-omics, imaging, and real-world datasets; bfLEAP®, a causal and graph-analytic AI platform originally developed at Johns Hopkins University Applied Physics Laboratory under an exclusive license, used for patient subgroup identification, biomarker discovery, and drug target prioritization; and bfARENAS™, a scenario-based decision engine for portfolio strategy and clinical trial design. BullFrog Data Networks® and an in-licensed drug pipeline (BF-222 glioblastoma, BF-223 mebendazole prodrug, BF-114 obesity/liver disease) round out the offering.

The company makes money primarily through project-based, quote-priced platform service engagements with large pharma, supplemented by milestone payments tied to defined deliverables and optional exclusive-rights licensing on identified drug targets. Its first commercial feasibility agreement, signed March 30, 2026 with a top-5 global pharmaceutical company for major depressive disorder target identification, is its anchor commercial reference. Other named collaborators include Eleison Pharmaceuticals, H. Lee Moffitt Cancer Center, and the Lieber Institute for Brain Development (LIBD). As of December 31, 2025, BullFrog reported an accumulated deficit of approximately $23.3 million and a cash balance of approximately $2.3 million; a Nasdaq compliance matter was resolved in April 2026, with management stating the runway now extends into late 2027.

Short descriptiontext

BullFrog AI (NASDAQ: BFRG) sells an end-to-end explainable AI platform — bfPREP, bfLEAP, and bfARENAS — to pharmaceutical, biotech, and research institution customers for clinical data harmonization, biomarker and target discovery, and portfolio decision support.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGaithersburg, United States
HQ citystring
Gaithersburg
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, biomedical data analytics, clinical data harmonization, patient stratification software, pharmaceutical AI platform
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Software Publishers5132
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Services-Prepackaged Software7372
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
Product category
AI-Driven Drug Development Platform
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Platform Service Fees
TypeSubscription Recurring
Description

Fees charged for using bfPREP™, bfLEAP®, and bfARENAS™ platforms for pharmaceutical data analysis and decision support. Engagements begin with collaborative data audit, followed by customized AI model development and ongoing high-value outputs.

manilatimes.net
2Milestone Payments
TypeProfessional Services
Description

Payments tied to defined deliverables in commercial agreements with pharmaceutical partners. The March 2026 top-5 pharma agreement includes milestone payments for specific achievements in drug target identification.

quiverquant.com
3In-Licensed Drug Pipeline
TypeLicensing Royalties
Description

Revenue potential from proprietary drug development programs including BF-222 (glioblastoma), BF-223 (novel mebendazole prodrug), and BF-114 (obesity/liver diseases) through exclusive worldwide license agreements.

news.biobuzz.io
4Exclusive Rights Options
TypeLicensing Royalties
Description

Partners may secure exclusive rights to target candidates for R&D purposes, generating potential future revenue streams.

manilatimes.net
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1bfPREP™
Description

AI-powered data preparation platform for life sciences that transforms raw, fragmented biomedical data into clean, harmonized, AI-ready assets. Includes data cleaning, harmonization, and feature engineering capabilities.

bullfrogai.com
+3 more records
Core offering1 text field

BullFrog AI develops and licenses an end-to-end AI-driven drug development platform consisting of bfPREP™ for data cleaning and harmonization, bfLEAP® for causal AI biomedical analysis, and bfARENAS™ for scenario-based portfolio decision-making. The company sells platform service engagements and project-based contracts to pharmaceutical, biotechnology, and research institution clients to identify drug targets, stratify patients, and optimize clinical trial design.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Nearly 3x improvement in mean survival identified in pancreatic cancer patient subgroups through biomarker analysis
+2 more records
Product overview1 text field

BullFrog AI offers an end-to-end AI-driven drug development platform consisting of three integrated products: bfPREP™ for AI-powered data cleaning and harmonization, bfLEAP® for causal AI analysis and biomedical data interpretation, and bfARENAS™ for scenario-based decision-making in portfolio strategy and clinical trial design. The platform is complemented by BullFrog Data Networks® for multi-omics integration and a strategic CNS partnership with the Lieber Institute. The company also maintains an in-licensed drug pipeline of proprietary candidates (BF-222, BF-223, BF-114).

Product and service6 records
1bfLEAP®
CategoryBiomedical Data Analysis Platform
Description

Award-winning explainable AI platform that uncovers biologically meaningful patterns, subgroups, and drivers hidden within complex, multimodal datasets using graph analytics and Random Subspace Mixture Models. Enables patient subgroup identification, drug target discovery, biomarker identification, and clinical trial optimization for pharmaceutical and biotech R&D teams.

2bfPREP™
CategoryData Preparation and Harmonization Platform
Description

AI-driven data cleaning and harmonization platform that transforms raw, fragmented biomedical data into clean, AI-ready assets. Eliminates errors, normalizes formats across clinical, omics, imaging, and real-world data, and prepares data for downstream analysis. Reduces data prep time by up to 80%.

3bfARENAS™
CategoryPortfolio Decision Support Platform
Description

Scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design. Evaluates drug programs, targets, biomarkers, and trial designs through head-to-head comparison across multiple strategic scenarios, producing transparent and defensible rankings to drive portfolio confidence.

4BullFrog Data Networks®
CategoryMulti-Omics Bioinformatics Platform
Description

AI-powered bioinformatics solution that integrates public, proprietary, and custom multi-omics datasets using the bfLEAP® platform to reveal actionable biological insights for precision drug discovery, target validation, and clinical development.

5In-Licensed Drug Pipeline (BF-222, BF-223, BF-114)
CategoryDrug Development Pipeline Assets
Description

Proprietary in-licensed drug development pipeline including BF-222 (repurposed small molecule for glioblastoma), BF-223 (novel mebendazole prodrug with US patent for glioblastoma), and BF-114 (nucleic acid therapeutic for obesity and chronic liver diseases), held under exclusive worldwide license agreements.

6CNS Target Discovery
CategoryCNS Drug Target Discovery Service
Description

Target discovery offering leveraging BullFrog AI's causal AI and machine learning technology alongside the Lieber Institute for Brain Development's brain expression data to enable discovery and development of precision treatments for CNS disorders including major depression, schizophrenia, and bipolar disorder.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Top 5 Global Pharmaceutical Company
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-30
Description

First commercial feasibility agreement signed March 30, 2026 to use bfLEAP® platform for identifying and prioritizing drug targets in major depressive disorder (MDD). Agreement includes milestone payments tied to defined deliverables and option for exclusive rights to final selected target candidate. Market for MDD drugs valued at over $8 billion in 2025, projected to exceed $11 billion by 2032.

manilatimes.net
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnership for CNS drug target discovery. LIBD maintains the largest collection of postmortem brains for neuropsychiatric disorder study. Partnership has identified novel subgroups within major depression, schizophrenia, and bipolar disorder using BullFrog AI's causal AI and machine learning technology.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration using bfPREP™ and bfLEAP® platforms for pancreatic cancer research. Converted over 10,000 pages of clinical PDF documents into clean, integrated data. Identified patient subgroups showing nearly threefold improvement in mean survival. Findings presented at 2026 ASCO GI Symposium.

4H. Lee Moffitt Cancer Center
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on pancreatic cancer research using bfLEAP® platform. Identified key biomarkers in glufosfamide clinical trial data demonstrating enhanced survival in patient subgroups. Research findings accepted for presentation at American Society of Clinical Oncology's Gastrointestinal Cancers Symposium.

manilatimes.net
Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Partnership with CRO Sygnature Discovery mentioned in investor webinar announcement, indicating collaboration in drug discovery services.

6Xtalks Life Sciences
Strategic tierSecondaryTypeGTM or Marketing Partner
Description

Partnership for webinar hosting and educational content. Xtalks hosted 'Turning AI Recommendations into Clear, Defensible Decisions' webinar on March 27, 2026 featuring BullFrog AI's Juan Felipe Beltrán.

quiverquant.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Publicly traded AI drug discovery platform (NASDAQ: RXRX) combining high-throughput biology with ML to identify novel therapeutics. Most directly comparable to BullFrog's bfLEAP target-discovery and patient-stratification capabilities.

TypeDirect peer
Description

Publicly traded computational chemistry and molecular simulation platform (NASDAQ: SDGR) serving pharma R&D with physics-based and AI-driven drug design software. Comparable to BullFrog as a software-first AI platform selling into pharma R&D budgets.

TypeDirect peer
Description

AI-driven drug discovery company combining ML with automated lab capabilities to design and develop small-molecule therapeutics. Directly comparable AI-first pharma services platform with similar enterprise-pharma customer profile.

TypeDirect peer
Description

Clinical-stage AI drug discovery company with end-to-end platform spanning target identification through clinical development, including proprietary pipeline assets. Highly comparable end-to-end AI workflow plus in-house pipeline model.

TypeDirect peer
Description

AI-powered drug discovery and development platform integrating human data and ML across the pharma R&D value chain. Closely comparable to BullFrog's data-network-driven approach and platform-plus-pipeline hybrid model.

TypeDirect peer
Description

AI-driven small-molecule drug discovery company using structure-based deep learning to accelerate hit identification and lead optimization. Comparable enterprise-pharma AI target-discovery offering.

TypeDirect peer
Description

AI-driven drug discovery company combining knowledge graphs and ML to identify novel targets and develop therapeutics. Comparable AI target-identification and patient-stratification use cases, with public listing (AMS: BAI).

TypeEmerging player
Description

AI-biopharma company applying ML to multi-omics and real-world patient data for target discovery and clinical trial optimization in oncology and other therapeutic areas. Comparable AI-platform-for-pharma model with focus on biomedical data analytics.

9Isomorphic Labs
TypeBroad incumbent
Description

Alphabet-owned AI drug discovery subsidiary leveraging DeepMind's protein-structure prediction and broader ML capabilities. Broad incumbent competitor with deeper resources but similar AI-first pharma platform thesis.

TypeOthers
Description

Provides foundation models and compute infrastructure (BioNeMo, Clara) used by AI drug discovery platforms including BullFrog peers. Adjacent enabling technology rather than direct competitor, but a strategic supplier and ecosystem reference point for AI-driven pharma workflows.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BullFrog AI

AI-Driven Drug Development Platformbullfrogai.com

BullFrog AI (NASDAQ: BFRG) sells an end-to-end explainable AI platform — bfPREP, bfLEAP, and bfARENAS — to pharmaceutical, biotech, and research institution customers for clinical data harmonization, biomarker and target discovery, and portfolio decision support.

What BullFrog AI does

BullFrog AI Holdings, Inc. (NASDAQ: BFRG) is a publicly traded, AI-focused drug development technology company founded in 2021 and headquartered in Gaithersburg, Maryland. It sells an end-to-end explainable AI workflow to pharmaceutical, biotechnology, and research institution buyers, anchored on three integrated products: bfPREP™, which cleans and harmonizes fragmented clinical, multi-omics, imaging, and real-world datasets; bfLEAP®, a causal and graph-analytic AI platform originally developed at Johns Hopkins University Applied Physics Laboratory under an exclusive license, used for patient subgroup identification, biomarker discovery, and drug target prioritization; and bfARENAS™, a scenario-based decision engine for portfolio strategy and clinical trial design. BullFrog Data Networks® and an in-licensed drug pipeline (BF-222 glioblastoma, BF-223 mebendazole prodrug, BF-114 obesity/liver disease) round out the offering.

The company makes money primarily through project-based, quote-priced platform service engagements with large pharma, supplemented by milestone payments tied to defined deliverables and optional exclusive-rights licensing on identified drug targets. Its first commercial feasibility agreement, signed March 30, 2026 with a top-5 global pharmaceutical company for major depressive disorder target identification, is its anchor commercial reference. Other named collaborators include Eleison Pharmaceuticals, H. Lee Moffitt Cancer Center, and the Lieber Institute for Brain Development (LIBD). As of December 31, 2025, BullFrog reported an accumulated deficit of approximately $23.3 million and a cash balance of approximately $2.3 million; a Nasdaq compliance matter was resolved in April 2026, with management stating the runway now extends into late 2027.

BullFrog AI firmographics

Firmographics
Name
BullFrog AI
Legal name
Bullfrog AI Holdings, Inc.
Website
https://bullfrogai.com
Company type
Public
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
BullFrog AI (NASDAQ: BFRG) sells an end-to-end explainable AI platform — bfPREP, bfLEAP, and bfARENAS — to pharmaceutical, biotech, and research institution customers for clinical data harmonization, biomarker and target discovery, and portfolio decision support.
Ownership category
akta.pro rank

BullFrog AI industry classification

Industry
Product category
AI-Driven Drug Development Platform
NAICS
Software Publishers (5132), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Prepackaged Software (7372), Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • AI drug discovery
  • Biomedical data analytics
  • Clinical data harmonization
  • Patient stratification software
  • Pharmaceutical AI platform

Where BullFrog AI is headquartered

Location

Headquarters

HQ city
Gaithersburg
HQ country
United States
HQ region
North America

Offices1 record

Markets served

BullFrog AI business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Platform Service Fees: Fees charged for using bfPREP™, bfLEAP®, and bfARENAS™ platforms for pharmaceutical data analysis and decision support. Engagements begin with collaborative data audit, followed by customized AI model development and ongoing high-value outputs.
  2. Milestone Payments: Payments tied to defined deliverables in commercial agreements with pharmaceutical partners. The March 2026 top-5 pharma agreement includes milestone payments for specific achievements in drug target identification.
  3. In-Licensed Drug Pipeline: Revenue potential from proprietary drug development programs including BF-222 (glioblastoma), BF-223 (novel mebendazole prodrug), and BF-114 (obesity/liver diseases) through exclusive worldwide license agreements.
  4. Exclusive Rights Options: Partners may secure exclusive rights to target candidates for R&D purposes, generating potential future revenue streams.

Go-to-market motion3 records

Distribution channels1 record

Marketing channels7 records

BullFrog AI product offering

Product offering

Core offering

BullFrog AI develops and licenses an end-to-end AI-driven drug development platform consisting of bfPREP™ for data cleaning and harmonization, bfLEAP® for causal AI biomedical analysis, and bfARENAS™ for scenario-based portfolio decision-making. The company sells platform service engagements and project-based contracts to pharmaceutical, biotechnology, and research institution clients to identify drug targets, stratify patients, and optimize clinical trial design.

Product overview

BullFrog AI offers an end-to-end AI-driven drug development platform consisting of three integrated products: bfPREP™ for AI-powered data cleaning and harmonization, bfLEAP® for causal AI analysis and biomedical data interpretation, and bfARENAS™ for scenario-based decision-making in portfolio strategy and clinical trial design. The platform is complemented by BullFrog Data Networks® for multi-omics integration and a strategic CNS partnership with the Lieber Institute. The company also maintains an in-licensed drug pipeline of proprietary candidates (BF-222, BF-223, BF-114).

Differentiator

Problem solved

Functional benefit

Brands

  • bfPREP™: AI-powered data preparation platform for life sciences that transforms raw, fragmented biomedical data into clean, harmonized, AI-ready assets. Includes data cleaning, harmonization, and feature engineering capabilities.
  • bfLEAP®
  • bfARENAS™
  • BullFrog Data Networks®

Products and services

  • bfLEAP® Award-winning explainable AI platform that uncovers biologically meaningful patterns, subgroups, and drivers hidden within complex, multimodal datasets using graph analytics and Random Subspace Mixture Models. Enables patient subgroup identification, drug target discovery, biomarker identification, and clinical trial optimization for pharmaceutical and biotech R&D teams.
  • bfPREP™ AI-driven data cleaning and harmonization platform that transforms raw, fragmented biomedical data into clean, AI-ready assets. Eliminates errors, normalizes formats across clinical, omics, imaging, and real-world data, and prepares data for downstream analysis. Reduces data prep time by up to 80%.
  • bfARENAS™ Scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design. Evaluates drug programs, targets, biomarkers, and trial designs through head-to-head comparison across multiple strategic scenarios, producing transparent and defensible rankings to drive portfolio confidence.
  • BullFrog Data Networks® AI-powered bioinformatics solution that integrates public, proprietary, and custom multi-omics datasets using the bfLEAP® platform to reveal actionable biological insights for precision drug discovery, target validation, and clinical development.
  • In-Licensed Drug Pipeline (BF-222, BF-223, BF-114) Proprietary in-licensed drug development pipeline including BF-222 (repurposed small molecule for glioblastoma), BF-223 (novel mebendazole prodrug with US patent for glioblastoma), and BF-114 (nucleic acid therapeutic for obesity and chronic liver diseases), held under exclusive worldwide license agreements.
  • CNS Target Discovery Target discovery offering leveraging BullFrog AI's causal AI and machine learning technology alongside the Lieber Institute for Brain Development's brain expression data to enable discovery and development of precision treatments for CNS disorders including major depression, schizophrenia, and bipolar disorder.

Quantifiable outcome

  • Nearly 3x improvement in mean survival identified in pancreatic cancer patient subgroups through biomarker analysis
  • +2 more outcomes

Companies that use BullFrog AI

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

BullFrog AI technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature7 records

BullFrog AI partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and secondary.

  • Top 5 Global Pharmaceutical CompanycoreStrategic or Co-development Partner · 30 March 2026First commercial feasibility agreement signed March 30, 2026 to use bfLEAP® platform for identifying and prioritizing drug targets in major depressive disorder (MDD). Agreement includes milestone payments tied to defined deliverables and option for exclusive rights to final selected target candidate. Market for MDD drugs valued at over $8 billion in 2025, projected to exceed $11 billion by 2032.
  • Lieber Institute for Brain Development (LIBD)coreStrategic or Co-development PartnerStrategic partnership for CNS drug target discovery. LIBD maintains the largest collection of postmortem brains for neuropsychiatric disorder study. Partnership has identified novel subgroups within major depression, schizophrenia, and bipolar disorder using BullFrog AI's causal AI and machine learning technology.
  • Eleison PharmaceuticalscoreStrategic or Co-development PartnerCollaboration using bfPREP™ and bfLEAP® platforms for pancreatic cancer research. Converted over 10,000 pages of clinical PDF documents into clean, integrated data. Identified patient subgroups showing nearly threefold improvement in mean survival. Findings presented at 2026 ASCO GI Symposium.
  • H. Lee Moffitt Cancer CentercoreStrategic or Co-development PartnerCollaboration on pancreatic cancer research using bfLEAP® platform. Identified key biomarkers in glufosfamide clinical trial data demonstrating enhanced survival in patient subgroups. Research findings accepted for presentation at American Society of Clinical Oncology's Gastrointestinal Cancers Symposium.
  • Sygnature DiscoverysecondaryStrategic or Co-development PartnerPartnership with CRO Sygnature Discovery mentioned in investor webinar announcement, indicating collaboration in drug discovery services.
  • Xtalks Life SciencessecondaryGTM or Marketing PartnerPartnership for webinar hosting and educational content. Xtalks hosted 'Turning AI Recommendations into Clear, Defensible Decisions' webinar on March 27, 2026 featuring BullFrog AI's Juan Felipe Beltrán.

Scale indicators12 records

Recent moves7 records

Expansion highlights5 records

BullFrog AI competitors and assessment

Company assessment

Direct peers

  • Recursion Pharmaceuticals: Publicly traded AI drug discovery platform (NASDAQ: RXRX) combining high-throughput biology with ML to identify novel therapeutics. Most directly comparable to BullFrog's bfLEAP target-discovery and patient-stratification capabilities.
  • Schrödinger: Publicly traded computational chemistry and molecular simulation platform (NASDAQ: SDGR) serving pharma R&D with physics-based and AI-driven drug design software. Comparable to BullFrog as a software-first AI platform selling into pharma R&D budgets.
  • Exscientia: AI-driven drug discovery company combining ML with automated lab capabilities to design and develop small-molecule therapeutics. Directly comparable AI-first pharma services platform with similar enterprise-pharma customer profile.
  • Insilico Medicine: Clinical-stage AI drug discovery company with end-to-end platform spanning target identification through clinical development, including proprietary pipeline assets. Highly comparable end-to-end AI workflow plus in-house pipeline model.
  • Valo Health: AI-powered drug discovery and development platform integrating human data and ML across the pharma R&D value chain. Closely comparable to BullFrog's data-network-driven approach and platform-plus-pipeline hybrid model.
  • Atomwise: AI-driven small-molecule drug discovery company using structure-based deep learning to accelerate hit identification and lead optimization. Comparable enterprise-pharma AI target-discovery offering.
  • BenevolentAI: AI-driven drug discovery company combining knowledge graphs and ML to identify novel targets and develop therapeutics. Comparable AI target-identification and patient-stratification use cases, with public listing (AMS: BAI).

Emerging players

  • Owkin: AI-biopharma company applying ML to multi-omics and real-world patient data for target discovery and clinical trial optimization in oncology and other therapeutic areas. Comparable AI-platform-for-pharma model with focus on biomedical data analytics.

Broad incumbents

  • Isomorphic Labs: Alphabet-owned AI drug discovery subsidiary leveraging DeepMind's protein-structure prediction and broader ML capabilities. Broad incumbent competitor with deeper resources but similar AI-first pharma platform thesis.

Others

  • NVIDIA (BioNeMo / Clara): Provides foundation models and compute infrastructure (BioNeMo, Clara) used by AI drug discovery platforms including BullFrog peers. Adjacent enabling technology rather than direct competitor, but a strategic supplier and ecosystem reference point for AI-driven pharma workflows.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

BullFrog AI social profiles

Digital presence

BullFrog AI compliance and trust

Trust signal

Compliance3 records

BullFrog AI financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BullFrog AI leadership team

Management profile

Number of profiles

Profiles15 records

BullFrog AI funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BullFrog AI M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BullFrog AI

What does BullFrog AI do?

BullFrog AI develops and licenses an end-to-end AI-driven drug development platform consisting of bfPREP™ for data cleaning and harmonization, bfLEAP® for causal AI biomedical analysis, and bfARENAS™ for scenario-based portfolio decision-making. The company sells platform service engagements and project-based contracts to pharmaceutical, biotechnology, and research institution clients to identify drug targets, stratify patients, and optimize clinical trial design.

Is BullFrog AI a public or private company?

BullFrog AI is a public company. It is classified as public and is currently operating.

When was BullFrog AI founded?

BullFrog AI was founded in 2021. It employs 11 to 50 people.

Where is BullFrog AI based?

BullFrog AI is headquartered in Gaithersburg, United States, in the North America region.

How does BullFrog AI make money?

Four revenue lines are on record. Platform Service Fees are the primary driver. The others are milestone Payments, in-Licensed Drug Pipeline and exclusive Rights Options.

Who are BullFrog AI's main competitors?

Direct peers on record are Recursion Pharmaceuticals, Schrödinger, Exscientia, Insilico Medicine, Valo Health, Atomwise and BenevolentAI. Owkin is listed as an emerging player. Isomorphic Labs is listed as a broad incumbent. NVIDIA (BioNeMo / Clara) is listed as an others.

Does BullFrog AI have an API?

No public API is recorded for BullFrog AI.

What industry is BullFrog AI in?

BullFrog AI's product category is AI-Driven Drug Development Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics). Its NAICS code is 5132 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooBullfrog AI Holdings Inc. (BFRG) Reports Q3 Loss, Lags Revenue EstimatesBullfrog AI Holdings reported a Q3 loss of $0.11 per share, missing the consensus estimate of $0.09, and revenues of $0.06 million, down 71.1% from the $0.08 million consensus. The stock has fallen 37.4% year-to-date versus the S&P 500's 10.9% gain.TradingViewBullFrog AI 3Q 2026: Revenue $63.58K, EPS ($0.11) — 10-Q SummaryBullFrog AI reported Q3 2026 revenue of $63.58K, down 24% year over year, with a net loss of $2.01M. The company completed a feasibility agreement with a global pharmaceutical company, but cash of $5.1M is insufficient for planned operations beyond the filing date.Defense WorldBullfrog AI Holdings, Inc. (NASDAQ:BFRGW) Stock Short Interest Report for OctoberBullfrog AI Holdings saw short interest fall 34.5% to 4,483 shares as of October 15th. Citadel Advisors acquired a new stake of 361,546 shares, valued at about $257,000. The stock opened at $0.11, with a 50-day moving average of $0.12.American Banking and Market NewsBullfrog AI Holdings, Inc. (NASDAQ:BFRGW) Stock Short Interest Report for OctoberBullfrog AI Holdings saw short interest fall 34.5% to 4,483 shares as of October 15th. The stock opened at $0.11, and Citadel Advisors bought a new stake of 361,546 shares in Q2.Defense WorldBullfrog AI Holdings Inc. (NASDAQ:BFRG) Sees Significant Growth in Short InterestShort interest in Bullfrog AI Holdings rose 626.5% to 739,209 shares as of September 30th. The company reported a loss of $0.07 per share for the quarter, beating estimates, and insiders bought shares, including CEO Vininder Singh's purchase of 75,000 shares.American Banking and Market NewsBullfrog AI (NASDAQ:BFRG) & Twist Bioscience (NASDAQ:TWST) Head-To-Head ContrastTwist Bioscience and Bullfrog AI are compared on analyst ratings, valuation, and profitability. Twist Bioscience has a stronger consensus rating (2.46 vs 1.50) and a price target of $128.17, implying 19.79% upside, while Bullfrog AI shows lower revenue and higher earnings. Twist Bioscience is also more profitable and less volatile.American Banking and Market NewsBullfrog AI Holdings, Inc. (NASDAQ:BFRGW) Stock Short Interest Jumps 196.7%Short interest in Bullfrog AI Holdings rose 196.7% to 6,845 shares as of September 30th. Citadel Advisors acquired a new position of 361,546 shares, valued at about $257,000. The stock opened at $0.14, with a 52-week range of $0.08 to $0.65.Ticker ReportComparing Bullfrog AI (NASDAQ:BFRG) & iSpecimen (NASDAQ:ISPC)Bullfrog AI and iSpecimen are compared on valuation, earnings, and institutional ownership. Bullfrog AI beats iSpecimen on 8 of 12 factors, including lower price-to-earnings ratio and higher earnings. Bullfrog AI has a beta of -2.73, indicating lower volatility than iSpecimen's 1.65.YahooBullFrog AI Advances Major Depressive Disorder Drug Discovery Program With Global Pharma PartnerBullFrog AI identified and prioritized novel therapeutic targets for major depressive disorder with a top-five global pharmaceutical company, using its AI platform on neuropsychiatric multi-omic datasets. The company did not disclose financial terms or specific targets, and the work is not clinical validation. The company is also applying its technology to schizophrenia and bipolar disorder.American Banking and Market NewsComparing Bullfrog AI (NASDAQ:BFRG) & Maravai LifeSciences (NASDAQ:MRVI)Maravai LifeSciences beats Bullfrog AI on 8 of 14 comparison factors, including institutional ownership and analyst ratings. Maravai has a consensus target price of $6.83, implying a 13.50% downside, while Bullfrog AI has a lower rating score. Maravai is also more profitable and less volatile.